Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.

Petit, A M

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. [electronic resource] - The American journal of pathology Dec 1997 - 1523-30 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

0002-9440


Adenocarcinoma--drug therapy
Animals
Antibodies, Monoclonal--pharmacology
Breast Neoplasms--drug therapy
Carcinoma, Squamous Cell--drug therapy
Dose-Response Relationship, Drug
Down-Regulation--drug effects
Endothelial Growth Factors--metabolism
Epidermal Growth Factor--immunology
Gene Expression Regulation, Neoplastic
Humans
Immunoenzyme Techniques
Lymphokines--metabolism
Mice
Mice, Nude
Neoplasm Transplantation
Neovascularization, Pathologic--drug therapy
Neutralization Tests
Receptor, ErbB-2--immunology
Signal Transduction--physiology
Tumor Cells, Cultured
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors